EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 277 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR The American Society of Clinical Oncology and the American Cancer Society:... February 1, 2022 Long-Term Survival in a Significant Proportion of Patients with a 1p/19q... June 28, 2022 Job Loss During Cancer: How to Cope and Continue Treatment September 24, 2020 FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection October 2, 2024 Load more HOT NEWS EMA Recommends Extension of Indications for Cemiplimab EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp 2023 ASCO Annual Meeting Research Round Up: Progress in Preventing Melanoma... UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation
